Sammanfattning
Coping with the immune rejection of allotransplants or autologous cells in patients with an active sensitization towards their autoantigens and autoimmunity presently necessitates life-long immune suppressive therapy acting on the immune system as a whole, which makes the patients vulnerable to infections and increases their risk of developing cancer. New technologies to induce antigen selective long-lasting immunosuppression or immune tolerance are therefore much needed.
Originalspråk | engelska |
---|---|
Artikelnummer | e71981 |
Tidskrift | PLoS ONE |
Volym | 8 |
Nummer | 8 |
DOI | |
Status | Published - 2013 |
Ämnesklassifikation (UKÄ)
- Neurologi
- Kirurgi